Glaxo to launch five vaccines over five yearsGlaxoSmithKline said it expects to launch five major vaccines in the next five years with the potential to reach total annual sales between $10 billion and $18 billion.
Among the vaccines is Cervarix, a cervical-cancer vaccine, considered to be the most promising product of the group.
Filing for Cervarix approval in Europe is expected in early 2006 with a U.S. filing expected later next year. Glaxo said Cervarix could achieve sales between $3.5 billion and $7 billion.
Other vaccines being readied for launch by 2010 include Rotarix for gastroenteritis, Streptorix for pneumococcal infections, a combination vaccine for meningitis and an improved vaccine for influenza.